Jove
Visualize
Contact Us

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency.

Hamostaseologie·2015
Same author

Strong association of variants around FOXE1 and orofacial clefting.

Journal of dental research·2014
Same author

In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Aptamer-based modulation of blood coagulation.

Hamostaseologie·2011
Same author

Haemostasis management of massive bleeding.

Hamostaseologie·2011
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

[Anticoagulation].

B Pötzsch1

  • 1Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn. bernd.poetzsch@ukb.uni-bonn.de

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|April 30, 2013
PubMed
Summary
This summary is machine-generated.

Anticoagulant drugs, including new options beyond heparins and vitamin K antagonists, are vital for preventing and treating blood clots. Their effectiveness and safety in various conditions like deep venous thrombosis and arrhythmias are key areas of study.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: May 11, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Anticoagulant drugs are essential antithrombotic agents used for preventing and treating thromboembolic disorders.
  • Historically, heparins and vitamin K antagonists were the primary anticoagulants.
  • Newer anticoagulants with improved pharmacological profiles are now available.

Purpose of the Study:

  • To review the role of anticoagulants in preventing and treating thromboembolic disorders.
  • To discuss the impact of anticoagulants on deep venous thrombosis, pulmonary embolism, and cardiac arrhythmias.
  • To evaluate the potential benefits of newer anticoagulants compared to traditional ones.

Main Methods:

  • Review of existing literature on anticoagulant therapies.
  • Analysis of the efficacy and safety profiles of various anticoagulant classes.
  • Discussion of clinical applications in high-risk situations like orthopedic surgery and in patients with cardiac arrhythmias.

Main Results:

  • Anticoagulants significantly reduce the risk of venous thrombosis and fatal pulmonary embolisms, even in high-risk settings.
  • They are crucial for treating acute venous thrombosis and preventing recurrent events.
  • Long-term anticoagulation therapy effectively lowers thromboembolic risks in patients with cardiac arrhythmias.

Conclusions:

  • A wide range of anticoagulants are now available, offering improved pharmacological profiles.
  • The clinical utility of these newer agents in terms of enhanced efficacy, safety, and patient acceptance requires further investigation.
  • Anticoagulants remain central to managing and preventing a spectrum of thrombotic conditions.